Incyte Corporation

Healthcare · Biotechnology

Overall research band Exceptional

Quality Exceptional

Valuation Exceptional

Balance sheet Exceptional

Market confirmation Strong

One-minute company read

What this report can tell you now

What the company does

Incyte Corporation is a biopharmaceutical company based in Wilmington, Delaware, focused on the research, development, and global marketing of innovative therapies. Its main products include JAKAFI, used for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for various tumors; and ICLUSIG, a kinase inhibitor for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Incyte's pipeline features clinical-stage candidates such as ruxolitinib for steroid-refractory chronic graft-versus-host disease, itacitinib for newly diagnosed chronic GVHD, pemigatinib for several cancer types, Parsaclisib for lymphomas, and Retifanlimab for multiple cancer indications. The company generates revenue primarily through the sale of its proprietary therapies and maintains strategic alliances with pharmaceutical and biotech firms, including Novartis, Eli Lilly, Agenus, MorphoSys, and Xencor, to support clinical development and combination therapy trials.

The current research profile is Exceptional Compounder, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC52.7%Model input; read with the evidence status and period context.

Operating margin26.1%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years14.5%Model input; read with the evidence status and period context.

FCF margin26.3%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.